Physician profile
Ali Arif
NPI 1578124038
$1,387.60
in general payments reported to CMS, 2019-2025
18 companies · $925 in 2025
The $925 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $462 · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,341 · Education: $46.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.39 |
| Education | $46.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $252.00 | 2024-2025 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $223.48 | 2024-2025 | Acthar |
| Amgen INC. | $196.74 | 2024-2025 | Tavneos, Parsabiv, Aranesp |
| Otsuka America Pharmaceutical, INC. | $93.46 | 2025 | Jynarque, Voyxact |
| Akebia Therapeutics INC | $87.92 | 2024-2025 | Vafseo |
| Ani Pharmaceuticals, INC. | $87.36 | 2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals Lp | $83.79 | 2024-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $81.78 | 2025 | |
| Inspire Medical Systems, INC. | $47.64 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $46.67 | 2025 | |
| Calliditas Therapeutics US INC. | $34.77 | 2025 | Tarpeyo |
| Lilly USA, LLC | $26.43 | 2025 | Jardiance |
| Travere Therapeutics, INC. | $22.74 | 2025 | |
| Opko Pharmaceuticals, LLC | $21.60 | 2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $21.25 | 2024 | Ultomiris |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $20.61 | 2024 | |
| Scpharmaceuticals INC. | $20.00 | 2025 | |
| Apellis Pharmaceuticals, INC. | $19.36 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Arif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.